The Effect of Nutritional Therapy on Bone Mineral Density and Bone Metabolism in Pediatric Crohn Disease.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
pubmed:
16
2
2021
medline:
10
7
2021
entrez:
15
2
2021
Statut:
ppublish
Résumé
Both the inflammatory burden of Crohn disease (CD) and corticosteroids have a negative effect on bone density. Exclusive enteral nutrition (EEN) avoids corticosteroids and promotes endoscopic healing. We aimed to explore the effect of nutritional therapy on bone health in pediatric CD. This was a planned sub-study of a clinical trial enrolling children with new-onset mild-moderate CD. Children were randomized to either 6 weeks EEN followed by 6 weeks 25% partial enteral nutrition (PEN) or 6 weeks of 50% PEN with a CD exclusion diet followed by 6 weeks of 25% PEN with exclusion diet. Bone formation and resorption were measured at baseline, week 12 and week 24 by serum C-Propeptide of Type I Procollagen (CICP) and type I Collagen N-Telopeptide (NTX), respectively. Bone mineral density (BMD) was measured by dual energy X-ray absorptiometry (DXA) scan at baseline and week 24. Median CICP improved from 130 ng/mL (106-189) at baseline to 223 (143-258) at week 12 and 193 (143-252) at week 24 (P = 0.016 for both, n = 29 children). Median NTX remained unchanged (P = 0.45 and P = 0.45). Thirty-six children had DXA scans performed at diagnosis; 81% and 33% had z scores of <-1 and <-2, respectively. DXA z scores did not improve from baseline (adjusted total body less head [TBLH] BMD -1.62 ± 0.87) to week 24 (-1.76 ± 0.75; P = 0.30, n = 21 with both scans). Low bone density is common in new-onset mild-moderate pediatric CD. CICP, a sensitive marker of bone formation, improved following dietary intervention but this was not associated with improved BMD.
Identifiants
pubmed: 33587407
doi: 10.1097/MPG.0000000000003073
pii: 00005176-202106000-00018
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
877-882Informations de copyright
Copyright © 2021 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Références
Zemel BS. Human biology at the interface of paediatrics: measuring bone mineral accretion during childhood. Ann Hum Biol 2012; 39:402–411.
Dubner SE, Shults J, Baldassano RN, et al. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology 2009; 136:123–130.
Casals-Seoane F, Chaparro M, Maté J, et al. Clinical course of bone metabolism disorders in patients with inflammatory bowel disease: a 5-year prospective study. Inflamm Bowel Dis 2016; 22:1929–1936.
Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012; 55:93–108.
DeFilippis EM, Sockolow R, Barfield E. Health care maintenance for the pediatric patient with inflammatory bowel disease. Pediatrics 2016; 138:e20151971.
Lev-Tzion R, Turner D. Is pediatric IBD treatment different than in adults? Minerva Gastroenterol Dietol 2012; 58:137–150.
Ruemmele FM, Veres G, Kolho KL, et al. European Crohn's and Colitis Organisation, European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014; 8:1179–1207.
Day AS, Lopez RN. Exclusive enteral nutrition in children with Crohn's disease. World J Gastroenterol 2015; 21:6809–6816.
Schwerd T, Frivolt K, Clavel T, et al. Exclusive enteral nutrition in active pediatric Crohn disease: effects on intestinal microbiota and immune regulation. J Allergy Clin Immunol 2016; 138:592–596.
Sylvester FA, Wyzga N, Hyams JS, et al. Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res 2002; 17:695–702.
Soo J, Malik BA, Turner JM, et al. Use of exclusive enteral nutrition is just as effective as corticosteroids in newly diagnosed pediatric Crohn's disease. Dig Dis Sci 2013; 58:3584–3591.
Whitten KE, Leach ST, Bohane TD, et al. Effect of exclusive enteral nutrition on bone turnover in children with Crohn's disease. J Gastroenterol 2010; 45:399–405.
Werkstetter KJ, Schatz SB, Alberer M, et al. Influence of exclusive enteral nutrition therapy on bone density and geometry in newly diagnosed pediatric Crohn's disease patients. Ann Nutr Metab 2013; 63:10–16.
Strisciuglio C, Scarpato E, Cenni S, et al. Improvement of body composition and bone mineral density after enteral nutrition in pediatric Crohn disease. Dig Liver Dis 2020; 52:630–636.
Levine A, Wine E, Assa A, et al. Crohn's disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology 2019; 157:440.e8–450.e8.
Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40:228–233.
van der Sluis IM, Hop WC, van Leeuwen JP, et al. A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy Dutch children and young adults. Horm Res 2002; 57:170–179.
Zemel BS, Kalkwarf HJ, Gilsanz V, et al. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab 2011; 96:3160–3169.
Pazianas M, Rhim AD, Weinberg AM, et al. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease. Ann N Y Acad Sci 2006; 1068:543–556.
Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated. Am J Gastroenterol 2005; 100:2031–2035.
Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 2006; 40:55–63.
Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 2004; 20:607–614.
Miheller P, Muzes G, Rácz K, et al. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. Inflamm Bowel Di 2007; 13:1379–1384.
Ryan BM, Russel MG, Schurgers L, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther 2004; 20:851–857.
Thayu M, Leonard MB, Hyams JS, et al. Reach Study Group. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol 2008; 6:1378–1384.
Griffin LM, Thayu M, Baldassano RN, et al. Improvements in bone density and structure during anti-TNF-α therapy in pediatric Crohn's disease. J Clin Endocrinol Metab 2015; 100:2630–2639.
Altowati MMA, Shepherd S, McMillan M, et al. Persistence of muscle-bone deficits following anti-tumour necrosis factor therapy in adolescents with Crohn disease. J Pediatr Gastroenterol Nutr 2018; 67:738–744.
DeBoer MD, Lee AM, Herbert K, et al. Increases in IGF-1 after anti-TNF-α therapy are associated with bone and muscle accrual in pediatric Crohn disease. J Clin Endocrinol Metab 2018; 103:936–945.